According to BeiGene's announcement, total revenue for the third quarter of 2026 was 12.774 billion yuan, up 26.8% year on year; net profit attributable to parent company owners was 2,785 billion yuan, up 304.3% year on year. Total revenue for the first three quarters of 2026 was 34.993 billion yuan, up 26.8% year on year; net profit attributable to parent company owners was 6.055 billion yuan, up 431.8% year on year. The increase in performance was mainly due to increased sales of authorized Baieze®, Baizean® and Amgen products.

According to BeiGene's announcement, total revenue for the third quarter of 2026 was 12.774 billion yuan, up 26.8% year on year; net profit attributable to parent company owners was 2,785 billion yuan, up 304.3% year on year. Total revenue for the first three quarters of 2026 was 34.993 billion yuan, up 26.8% year on year; net profit attributable to parent company owners was 6.055 billion yuan, up 431.8% year on year. The increase in performance was mainly due to increased sales of authorized Baieze®, Baizean® and Amgen products.